CytomX to Announce Q1 2024 Results and CX-904 Phase 1a Data on May 8

CytomX Therapeutics, Inc., a leader in the field of masked, conditionally activated biologic therapeutics, has announced that it will release its first quarter 2024 financial results and provide an initial update on the CX-904 Phase 1a dose escalation study on May 8, 2024, after the U.S. markets close. Following the release, the company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

Participants can access the live webcast through the Events and Presentations page on CytomX’s website. It is recommended to register for the conference call at least 10 minutes before the start time. An archived replay of the webcast will be available on the company’s website.

CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel conditionally activated, masked biologics, specifically designed for localization within the tumor microenvironment. The company's innovative pipeline is powered by its proprietary PROBODY® therapeutic platform, aiming to create safer, more effective cancer treatments.

The company’s pipeline consists of several therapeutic candidates that span multiple treatment modalities, including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators like cytokines. Among the clinical-stage candidates is CX-904, a masked, conditionally activated T-cell-engaging bispecific antibody. CX-904 targets the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells and is being developed in partnership with Amgen through a global co-development alliance.

Another candidate, CX-2051, is a masked, conditionally activated ADC directed towards the epithelial cell adhesion molecule, EpCAM. This molecule has potential applications across various EpCAM-expressing epithelial cancers. This ADC was discovered in collaboration with Immunogen, which is now part of AbbVie. Additionally, CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applications in both traditionally immuno-oncology-sensitive tumors and those that are typically resistant (cold tumors).

CytomX has established strategic collaborations with several leading oncology companies, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. These collaborations aim to advance the development and commercialization of CytomX’s novel conditionally activated treatments that promise to become the new standard-of-care in oncology.

The conference call on May 8th will provide valuable insights into the progress of CytomX’s groundbreaking CX-904 project, among other updates, and is an event of considerable interest to investors, researchers, and other stakeholders in the biopharmaceutical industry.